trending Market Intelligence /marketintelligence/en/news-insights/trending/b8j1uWOwARmhAlftZDHVUg2 content esgSubNav
In This List

Former Juniper exec joins 2X Oncology as CEO

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


Former Juniper exec joins 2X Oncology as CEO

2X Oncology Inc. named George Elston as CEO and a board member.

Elston was previously CFO of Juniper Pharmaceuticals Inc.

2X Oncology is a clinical stage company developing targeted therapeutics that leverage proprietary drug response predictor companion diagnostic technology to address unmet needs in women's cancer.